BridgeBio Oncology Therapeutics (BBOT) Interest & Investment Income (2024 - 2025)
BridgeBio Oncology Therapeutics (BBOT) posted Interest & Investment Income of $2.1 million for Q2 2025, up 4.31% sequentially from $2.0 million in Q1 2025, and down 15.04% YoY from $2.4 million in Q2 2024.
Powered by 
Analysis
BridgeBio Oncology Therapeutics (BBOT) Interest & Investment Income (2024 - 2025) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Interest & Investment Income for 2 years, with the latest figure at $2.1 million in Q2 2025.
- Quarterly Interest & Investment Income fell 15.04% year-over-year to $2.1 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $8.9 million (changed N/A YoY) and the FY2024 annual result came in at $8.4 million, changed N/A from the prior year.
- Interest & Investment Income climbed to $2.1 million in Q2 2025 per BBOT's latest filing, from $2.0 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $2.6 million in Q3 2024 and troughed at $1.2 million in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 67.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | 35.58 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 27.90 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 28.14 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 5.13 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 10.98 Mn |
| 10 | BridgeBio Oncology Therapeutics | 721.29 Mn | 495.58 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 1.99 Mn |
| Dec 31, 2024 | 2.25 Mn |
| Sep 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 2.44 Mn |
| Mar 31, 2024 | 1.21 Mn |